Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 16 de 16
Filtrar
1.
Clin Transl Oncol ; 21(6): 721-728, 2019 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-30374838

RESUMO

BACKGROUND: Advanced non-small cell lung cancer (NSCLC) has remained challenging to treat effectively. This study aimed to investigate the clinical effects and safety of immunotherapy with dendritic cells and cytokine-induced killer cells (DC-CIK) administered with chemotherapy (CT) in this malignancy. METHODS: We have developed a new clinical trial design termed as the prospective patient's preference-based study (PPPS). Consecutive patients (n = 135) with advanced NSCLC were treated with DC-CIK administered with CT or mono-therapy (CT or DC-CIK alone). RESULTS: For all the patients, the median PFS was 5.7 months and the median OS was 17.5 months. The 1-year PFS and OS rates were 29.4% and 58.2%, respectively. The 1-year PFS and OS rates for DC-CIK plus CT were significantly higher than that in the group of patients who received DC-CIK alone and CT alone (P < 0.05). The number of adoptively infused DC-CIK cells was associated with clinical efficacy. After adjusting for competing risk factors, DC-CIK combined with CT and infused number of CIKs remained independent predictors of PFS and OS. Phenotypic analysis of peripheral blood mononuclear cells showed that CD8+CD28+, and CD8+CD28- T cells, changed significantly in all groups (P < 0.01). The CD3+ T cells increased in the chemotherapy plus immunotherapy and the immunotherapy alone group (P < 0.01), while CD3-CD16+CD56 T cells decreased in the chemotherapy plus immunotherapy and the immunotherapy alone group (P < 0.01). CONCLUSIONS: DC-CIK combined with chemotherapy administration resulted in numerically superior PFS and OS compared with monotherapy in advanced NSCLC.


Assuntos
Carcinoma Pulmonar de Células não Pequenas/terapia , Células Matadoras Induzidas por Citocinas/transplante , Células Dendríticas/transplante , Imunoterapia Adotiva , Neoplasias Pulmonares/terapia , Preferência do Paciente , Linfócitos T/transplante , Adenocarcinoma/imunologia , Adenocarcinoma/patologia , Adenocarcinoma/terapia , Carcinoma Pulmonar de Células não Pequenas/imunologia , Carcinoma Pulmonar de Células não Pequenas/patologia , Carcinoma de Células Escamosas/imunologia , Carcinoma de Células Escamosas/patologia , Carcinoma de Células Escamosas/terapia , Células Matadoras Induzidas por Citocinas/imunologia , Células Dendríticas/imunologia , Feminino , Seguimentos , Humanos , Neoplasias Pulmonares/imunologia , Neoplasias Pulmonares/patologia , Masculino , Pessoa de Meia-Idade , Prognóstico , Estudos Prospectivos , Taxa de Sobrevida , Linfócitos T/imunologia
2.
Genet Mol Res ; 15(2)2016 Apr 07.
Artigo em Inglês | MEDLINE | ID: mdl-27173208

RESUMO

This study aimed to investigate the cytotoxicity of cytokine-induced killer cells (CIKs) and Her2 epitope peptide-sensitized dendritic cells (DCs), when co-cultured with Her2-positive MCF-7 cells. DCs were separated from the Her epitope peptide-sensitized peripheral blood; the Her epitope combines directly with the MHC-II molecule on the DC surface. The DCs were co-cultured with autologous CIKs. Lactate dehydrogenase (LDH) and ELISA kits were used to detect cytotoxicity of CIKs against MCF-7 breast cancer cells; IL-12 and IFN-γ levels were also analyzed in the supernatant of the culture medium. CIKs activated by DCs sensitized by anchored Her polypeptide antigen have greater cytotoxicity against MCF-7 than CIKs alone or non-anchored antigen sensitized DCs-CIKs (P < 0.01); the IL-12 and IFN-γ levels in the supernatant were higher than that of the control (P < 0.01). In conclusion, DCs anchored by polypeptide antigen alone or in combination with effector cells can be used to develop therapeutic DC vaccines against breast cancer.


Assuntos
Neoplasias da Mama/imunologia , Células Matadoras Induzidas por Citocinas/imunologia , Células Dendríticas/imunologia , Receptor ErbB-2/imunologia , Neoplasias da Mama/genética , Citotoxicidade Imunológica , Epitopos/imunologia , Feminino , Humanos , Interferon gama/genética , Interferon gama/metabolismo , Interleucina-12/genética , Interleucina-12/metabolismo , Células MCF-7
3.
São Paulo; s.n; 2016. [124] p. ilus, graf, tab.
Tese em Português | LILACS | ID: biblio-870892

RESUMO

Líquen plano (LP) é uma doença mucocutânea de natureza inflamatória crônica de etiologia ainda desconhecida. Alterações na resposta imune inata, como aos padrões moleculares associados à patógenos (PAMPs) e padrões moleculares associados ao dano (DAMPs) podem levar à inflamação crônica e contribuir com a patogênese do LP. OBJETIVO: Avaliar o efeito da ativação via o DAMP S100A8 e o receptor Toll-like 4 (TLR-4) em células Natural killer (NK) e TCD8 citotóxicas e suas subpopulações de memória/efetoras em pacientes com LP. MÉTODOS: Foram selecionados 25 pacientes com LP (22 mulheres, 3 homens) com idade média de 43,46 anos ± 8,46 e um grupo controle com 25 indivíduos (22 mulheres, 3 homens) com idade média de 42 anos ± 5,5. A determinação transcricional e da expressão por imunohistoquimica dos DAMPs S100A8, HMGB-1 e de TLR-4 e RAGE foi realizada em biópsias de lesões cutâneas de indivíduos com LP, e os níveis séricos de S100A8, HMGB-1, MICA e MICB foram determinados por ELISA. As células mononucleares (CMNs) de sangue periférico foram avaliadas por citometria de fluxo quanto a frequência de TNF, IL-1beta e o marcador de desgranulação CD107a em células TCD8+ e células NK CD56+ e suas subpopulações. A avaliação da via de sinalização de TLR em células TCD8+ purificadas e ativadas com S100A8 foi analisada por PCR array e a determinação da expressão de mRNA dos componentes do inflamassoma em células TCD8+ ativadas com S100A8 por PCR em tempo real. RESULTADOS: Foi evidenciado nos indivíduos com LP elevada expressão da proteína S100A8 nas lesões cutâneas e de HMGB-1, TLR-4 e RAGE na derme, em paralelo ao aumento da expressão de mRNAs para S100A8 e S100A9 e diminuição de RAGE. Além disto, uma elevação dos níveis séricos do dímero S100A8/A9 foi detectada nos pacientes comparados aos controles, ao contrário do DAMP HMGB-1 que mostrou níveis similares em ambos os grupos. A influência do S100A8 em células TCD8+ e células NK, foi analisada em CMNs pela ativação...


Lichen planus (LP) is a mucocutaneous inflammatory chronic disease of unknown etiology. Alterations in the innate immune response such as the pathogen-associated molecular pattern (PAMPs) and damage-associated molecular pattern (DAMPs) can lead to chronic inflammation and contribute to the pathogenesis of LP. OBJECTIVE: Evaluate the effect of the activation trough the DAMP S100A8 and the Toll-like receptor 4 (TLR-4) on the Natural killer cells (NK) and cytotoxic TCD8 cells and their memory / effector subsets in LP disease. METHODS: We selected 25 patients with LP (22 women, 3 men) with a mean age of 43.46 years ± 8.46 and a control group of 25 subjects (22 women, 3 men) with a mean age of 42 ± 5, 5. The transcriptional determination and protein expression by immunohistochemistry of DAMPs, S100A8 and HMGB-1 as well as TLR-4 and RAGE was performed on biopsies of skin lesions from patients with LP, and serum levels of S100A8, HMGB-1, MICA and MICB were determined by ELISA. Peripheral blood mononuclear cells (PBMCs) were assessed by flow cytometry to evaluate the frequency of TNF, IL-1beta and the degranulation marker CD107a in CD8+ T cells and CD56 + NK cells and their subsets. The evaluation of the TLR signaling pathway in purified CD8 + T cells activated with S100A8 were analyzed by PCR array and the determination of mRNA expression of inflammasome components on CD8 + T cells activated by S100A8 was measured by real time PCR. RESULTS: It was shown in the LP individuals an increased expression of the S100A8 protein in the cutaneous lesions and HMGB-1, TLR-4 and RAGE in the dermis, in parallel to increased level of mRNAs for S100A8 and S100A9 and decreased expression of RAGE. Moerover, increased serum levels of the dimer S100A8 / A9 was detected in patients compared to controls, in contrast to DAMP HMGB1 that revealed similar levels in both groups. The influence of S100A8 in CD8 + T cells and NK cells, was analyzed in PBMC activating with...


Assuntos
Humanos , Masculino , Feminino , Peptídeos Catiônicos Antimicrobianos , Células Matadoras Induzidas por Citocinas , Citotoxicidade Imunológica , Líquen Plano
4.
Genet Mol Res ; 14(4): 13208-14, 2015 Oct 27.
Artigo em Inglês | MEDLINE | ID: mdl-26535634

RESUMO

We cocultured cytokine-induced killer (CIK) cells with dendritic cells (DCs) in vitro and investigated their proliferation, immunophenotype changes, secretory cytokine levels, and their antitumor effects on acute myeloid leukemia (AML) cells. DCs and CIK cells were acquired from healthy human peripheral blood mononuclear cells and cocultured as an experimental group, while CIK cells were cultured alone as a control group. Cell numbers were counted by trypan blue staining, cytotoxic activity was measured by a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, cell phenotypes were detected by flow cytometry, and secreted levels of INF-γ and IL-12 were determined by enzyme-linked immunosorbent assay. The proliferation activity in the experimental group was noticeably higher than in the control group (P < 0.05). Under the same conditions, the ratio of CD3(+)CD56(+) and CD3(+)CD8(+) double-positive CIK cells was significantly elevated when cocultured with DCs (P < 0.05). Compared with the control group, the experimental group had significantly higher levels of secreted INF-γ and IL-12 in the supernatants after 3 days (P < 0.01 and P < 0.05, respectively). The antitumor effect of DC-CIK cells against leukemia cells was much higher than that of CIK cells at an effector-target ratio ranging from 2.5:1 to 20:1 (P < 0.05), and this effect was positively related to the effector-target ratio. The proliferation activity, level of secretory cytokines, and antitumor effect against AML cells of DC-CIK cells were significantly higher than in CIK cells. This study provides a theoretical and experimental basis for clinical immunotherapy using DC-CIK cells.


Assuntos
Células Matadoras Induzidas por Citocinas/imunologia , Citotoxicidade Imunológica , Células Dendríticas/imunologia , Leucemia/imunologia , Linhagem Celular Tumoral , Técnicas de Cocultura , Células Matadoras Induzidas por Citocinas/metabolismo , Citocinas/biossíntese , Células Dendríticas/metabolismo , Humanos , Imunofenotipagem , Leucemia/metabolismo , Ativação Linfocitária/imunologia , Fenótipo
5.
Genet Mol Res ; 14(3): 11543-50, 2015 Sep 28.
Artigo em Inglês | MEDLINE | ID: mdl-26436395

RESUMO

This study aimed to explore the clinical value of the CD4(+) T cell ATP levels in patients with renal cell carcinoma through the application of the ImmuKnow(TM)-Cylex(®) assay. We recruited 104 patients with renal cancer who had undergone surgery at Fuzhou General Hospital from March 2009 to June 2012, and were subsequently treated by dendritic cell and cytokine-induced killer cell bio-therapy or interferon-α therapy. The changes in CD4(+) T cell ATP levels were detected at the perioperative period and at 10 days, 1 month, 3 months, and 1 year after the surgery using the ImmuKnow assay. In addition, the differences in ATP levels in different therapy groups were compared and the prognosis conditions were analyzed. Our results demonstrated that no significant difference in the ATP levels occurred at different time points; furthermore, there were no obviously different ATP levels between the different therapy groups, and the ATP levels were found to have no clinical significance for the assessment of renal cancer prognosis. Overall, this study suggested that CD4(+) T cell ATP levels as detected by the ImmuKnow assay have no obvious clinical value in patients with renal cancer.


Assuntos
Carcinoma de Células Renais/imunologia , Imunoensaio/métodos , Neoplasias Renais/imunologia , Trifosfato de Adenosina/metabolismo , Adulto , Idoso , Idoso de 80 Anos ou mais , Linfócitos T CD4-Positivos , Carcinoma de Células Renais/tratamento farmacológico , Células Matadoras Induzidas por Citocinas/imunologia , Feminino , Humanos , Interferon-alfa/uso terapêutico , Estimativa de Kaplan-Meier , Masculino , Pessoa de Meia-Idade , Prognóstico
6.
Genet Mol Res ; 14(3): 10228-35, 2015 Aug 28.
Artigo em Inglês | MEDLINE | ID: mdl-26345959

RESUMO

To compare the efficacy of dendritic and cytokine-induced killer cells (DC-CIK) therapy combined with concurrent radiochemotherapy on stage IIIB non-small cell lung cancer. Sixty-three patients with stage IIIB non-small cell lung cancer were randomly divided into the study and control groups. The study group, comprising 30 patients, was treated with DC-CIK combined with docetaxel-cisplatin chemotherapy and synchronization conformal radiotherapy. The control group including 33 patients was only treated with docetaxel-cisplatin chemotherapy and synchronization conformal radiotherapy. The efficacy, Karnofsky performance score (KPS), tumor markers, 6-month and 12-month survival rate, T cell subsets, and adverse reactions of the two groups were compared. The response rate of the study group was 83.3% (25/30), and that of the control group was only 54.5% (18/33). Furthermore, the KPS, T cell subsets, and 12-month survival rate was significantly higher in the study group, and there were significant differences between the two groups. The two groups had no significant difference in adverse reactions. The combined DC-CIK therapy, with synchronous radiotherapy and chemotherapy to treat stage IIIB non-small cell lung cancer was superior to single synchronous radiotherapy and chemotherapy. The combined therapy can improve the life quality and prolong the survival time of the patients.


Assuntos
Carcinoma Pulmonar de Células não Pequenas/imunologia , Carcinoma Pulmonar de Células não Pequenas/terapia , Quimiorradioterapia , Células Matadoras Induzidas por Citocinas/imunologia , Células Dendríticas/imunologia , Neoplasias Pulmonares/imunologia , Neoplasias Pulmonares/terapia , Idoso , Biomarcadores Tumorais/metabolismo , Carcinoma Pulmonar de Células não Pequenas/mortalidade , Carcinoma Pulmonar de Células não Pequenas/patologia , Quimiorradioterapia/efeitos adversos , Feminino , Seguimentos , Humanos , Avaliação de Estado de Karnofsky , Neoplasias Pulmonares/mortalidade , Neoplasias Pulmonares/patologia , Subpopulações de Linfócitos/imunologia , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Taxa de Sobrevida , Fatores de Tempo , Resultado do Tratamento
7.
Genet Mol Res ; 14(2): 3082-9, 2015 Apr 10.
Artigo em Inglês | MEDLINE | ID: mdl-25966072

RESUMO

We examined the effects and molecular mechanism of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib on NKG2D ligand expression in human lung adenocarcinoma A549 cells and the cytotoxicity of cytokine-induced killer cells. Flow cytometry was used to detect NKG2D ligand expression in A549 cells under effects of erlotinib and EGFR downstream molecules, including LY294002 (phosphoinositide 3-kinase inhibitor), SB203580 (mitogen-activated protein kinase inhibitor), and STAT21 (signal transduction and transcription 3 inhibitor) after 24 h. A lactate dehydrogenase release assay was used to detect, at different effector-to-target ratios, the A549 cell killing activity of cytokine-induced killer cells before and after treatment with 10 mM erlotinib. Erlotinib suppressed MICA expression in A549 cells and upregulated MICB and UL16 binding protein 1 expression. EGFR downstream molecules mitogen-activated protein kinase and signal transduction and transcription 3 inhibitor did not affect the expression of NKG2D ligands in A549 cells. The phosphoinositide 3-kinase inhibitor reduced MICA expression in A549 cells, while erlotinib enhanced the killing sensitivity of cytokine-induced killer cells in A549 cells. The anti-lung carcinoma effects of EGFR tyrosine kinase inhibitor were associated with the sensitivity of lung cancer cells to enhanced immune cell killing.


Assuntos
Adenocarcinoma/terapia , Células Matadoras Induzidas por Citocinas/efeitos dos fármacos , Cloridrato de Erlotinib/farmacologia , Neoplasias Pulmonares/terapia , Adenocarcinoma/tratamento farmacológico , Adenocarcinoma/imunologia , Adenocarcinoma de Pulmão , Linhagem Celular Tumoral , Terapia Combinada , Células Matadoras Induzidas por Citocinas/imunologia , Receptores ErbB/antagonistas & inibidores , Citometria de Fluxo , Humanos , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias Pulmonares/imunologia , Subfamília K de Receptores Semelhantes a Lectina de Células NK/biossíntese
8.
Genet Mol Res ; 14(1): 898-905, 2015 Feb 02.
Artigo em Inglês | MEDLINE | ID: mdl-25730028

RESUMO

We investigated the clinical efficacy of adoptive cytokine-induced killer (CIK) cell and dendritic cell (DC) therapy plus intensity-modulated radiation therapy (IMRT) for treating elderly patients with esophageal carcinoma (EC). In total, 68 elderly patients with EC were randomized to receive IMRT plus DC-CIK immunotherapy (study group, N = 34) or IMRT only (control group, N = 34). Clinical efficacy, immune function, toxicity and side effects, and life quality were evaluated after treatment. The efficacy rate was significantly higher in the study group than in the control group. Remarkable increases were noted for quality of life and immune function in the study group relative to the control group. Regarding toxicity and side effects, compared with the control group, the study group displayed a higher fever rate, a lower incidence rate of bone marrow suppression, and a similar rate of digestive tract reactions. DC-CIK immunotherapy plus IMRT exhibited better short-term efficacy than IMRT alone in elderly patients with EC. The therapy could improve patients'quality of life and immune function, decrease bone marrow suppression, and lengthen survival time.


Assuntos
Carcinoma/radioterapia , Terapia Baseada em Transplante de Células e Tecidos , Células Matadoras Induzidas por Citocinas/transplante , Neoplasias Esofágicas/radioterapia , Idoso , Carcinoma/imunologia , Carcinoma/patologia , Células Matadoras Induzidas por Citocinas/imunologia , Células Dendríticas/imunologia , Células Dendríticas/transplante , Neoplasias Esofágicas/imunologia , Neoplasias Esofágicas/patologia , Feminino , Humanos , Imunoterapia/efeitos adversos , Masculino , Pessoa de Meia-Idade , Radioterapia de Intensidade Modulada/efeitos adversos
9.
Rev. Soc. Argent. Diabetes ; 49(2): 44-49, 2015.
Artigo em Espanhol | LILACS | ID: lil-774211

RESUMO

La diabetes tipo 1 (DT1) se asocia a un riesgo incrementado de complicaciones vasculares. Las citoquinas proinflamatorias IL-6, MCP-1 y TNF-α han sido implicadas en el desarrollo de estas complicaciones. El objetivo de este trabajo fue determinar los niveles plasmáticos de IL-6, MCP-1, TNF-α, PCRus y fibrinógeno (Fg) en pacientes infanto-juveniles con DT1 y su asociación con el grado de control glucémico y tiempo de evolución de la enfermedad. Se estudiaron 45 pacientes con DT1 (24 M/21 F), edad 11,2}1,8 años, con tiempo de evolución de la enfermedad de 3,1}3,0 años, sin complicaciones vasculares, que se compararon con 20 sujetos sanos. Se determinaron los niveles plasmáticos de IL-6, MCP-1 y TNF-α, Fg, PCRus, recuento de leucocitos, glucemia en ayunas y HbA1c. Se descartó la presencia de retinopatía y nefropatía. Los datos fueron analizados con el programa SPSS 15 para Windows. Los niños diabéticos presentaron niveles mayores de IL-6 (1,10}0,74 vs 0,68}0,19 pg/ml; p=0,005), MCP-1 (130}49 vs 95}18 pg/ml; p=0,02), PCRus (1,02}1,07 vs 0,43}026 mg/l; p=0,007), Fg (299}59 vs 246}18 mg/dl, p=0,0001), respecto de los controles. No se observaron diferencias significativas de TNF-α entre ambos grupos. Al agrupar a los diabéticos según el grado de control glucémico (HbA1c <8% y ≥8%) y el tiempo de evolución de la enfermedad (≤3 y >3 años), no se encontraron diferencias significativas en las moléculas estudiadas. En los diabéticos la HbA1c se correlaciono con IL-6, MCP-1 y PCRus. Estos resultados reflejan un estado proinflamatorio en la población diabética estudiada.


Assuntos
Células Matadoras Induzidas por Citocinas , Diabetes Mellitus Tipo 1 , Inflamação
10.
Salud(i)ciencia (Impresa) ; 20(7): 738-746, Ago.2014. graf
Artigo em Espanhol | LILACS | ID: lil-796498

RESUMO

La enfermedad celíaca (EC) es un trastorno inflamatorio crónico del intestino delgado inducido por la ingestión de gluten de trigo y otras prolaminas de cereales como cebada, centeno o avena. Afecta a las personas con susceptibilidad genética, y se manifiesta por una lesión de la mucosa intestinal (con linfocitosis intraepitelial, pérdida de vellosidades y remodelación tisular), y la presencia de anticuerpos antitransglutaminasa. El modelo patogénico más aceptado se basa en la activación de una respuesta de la inmunidad adaptativa tras la estimulación de linfocitos T CD4+ mediante péptidos de gluten modificados por la enzima transglutaminasa tisular presentados junto a moléculas HLA-DQ2 o DQ8, y la producción de citoquinas y otros mediadores pro inflamatorios. El gluten activa también la inmunidad innata local y los mecanismos de citotoxicidad sobre el epitelio mediados por linfocitos intraepiteliales. Aunque no se conoce bien cuál es el efecto o la implicación patogénica de los anticuerpos específicos de la EC, la disponibilidad de marcadores serológicos e inmunogenéticos como herramientas diagnósticas ha propiciado el avance en el conocimiento de la EC, y la revisión de los criterios diagnósticos, especialmente en los individuos adultos con expresión mínima o atípica de la enfermedad...


Assuntos
Humanos , Doença Celíaca/diagnóstico , Doença Celíaca/imunologia , Anticorpos , Células Matadoras Induzidas por Citocinas , Dieta Livre de Glúten , Glutens , Linfócitos T , Transglutaminases
11.
Clin Transl Oncol ; 15(10): 780-8, 2013 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-23359185

RESUMO

BACKGROUND: We hypothesized that combination of dendritic cell (DC) with autologous cytokine-induced killer (CIK) immunotherapy in setting of high-dose chemotherapy (HDC) would be effective for selected metastatic breast cancer (MBC) patients. PATIENTS AND METHODS: Our previous work showed thiotepa could eradicate breast cancer stem cells. From 2004 to 2009, 79 patients received standard dose chemotherapy (SDC) of 75 mg/m(2) docetaxel and 75 mg/m(2) thiotepa versus 87 patients of HDC + DC/CIK: 120 mg/m(2) docetaxel to mobilize peripheral CD34(+) progenitor cells, a sequence of HDC (120 mg/m(2) docetaxel, plus 175 mg/m(2) thiotepa) + DC/CIK, with or without 400 mg/m(2) carboplatin depending upon bone marrow function. The endpoints were response rates (RR), progression-free survival (PFS), and overall survival (OS). RESULTS: Compared with SDC, PFS and OS were improved in HDC + DC/CIK (median PFS 10.2 vs. 3.7 months, P < 0.001; median OS 33.1 vs. 15.2 months, P < 0.001). Patients of pre-menopausal, HDC as first-line treatment after metastasis, or with visceral metastasis showed prolonged PFS and OS. SDC group also achieved the similar response as previous reports. CONCLUSION: Our study demonstrated the novel combination of HDC with DC/CIK to be an effective choice for the selected MBC population, in which choosing appropriate chemo regimens played important roles, and also specific HDC regimen plus DC/CIK immunotherapy showed the clinical benefits compared with chemotherapy alone.


Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapêutico , Neoplasias da Mama/mortalidade , Carcinoma Ductal de Mama/mortalidade , Carcinoma Lobular/mortalidade , Células Matadoras Induzidas por Citocinas/transplante , Células Dendríticas/transplante , Imunoterapia Adotiva , Adulto , Idoso , Neoplasias da Mama/patologia , Neoplasias da Mama/terapia , Carboplatina/administração & dosagem , Carcinoma Ductal de Mama/secundário , Carcinoma Ductal de Mama/terapia , Carcinoma Lobular/secundário , Carcinoma Lobular/terapia , Terapia Combinada , Células Matadoras Induzidas por Citocinas/imunologia , Células Dendríticas/imunologia , Docetaxel , Feminino , Seguimentos , Humanos , Dose Máxima Tolerável , Pessoa de Meia-Idade , Metástase Neoplásica , Estadiamento de Neoplasias , Prognóstico , Taxa de Sobrevida , Taxoides/administração & dosagem , Tiotepa/administração & dosagem
12.
Rev. Méd. Clín. Condes ; 23(4): 446-457, jul. 2012. tab, ilus
Artigo em Espanhol | LILACS | ID: biblio-1145396

RESUMO

El sistema inmune media numerosas patologías, por lo que es importante conocer su estructura y funcionamiento. Se clasifica en innato y adquirido. El sistema inmune innato brinda una temprana e inespecífica respuesta contra los microorganismos. El sistema inmune adquirido humoral y celular nos brinda una respuesta específica para diferentes moléculas, posee memoria frente a los antígenos y diversidad para reaccionar a una gran variedad de antígenos.


The immune system mediates numerous pathologies functions por functioning it is important to know its structure and functioning. The immune system is classified into innate and adaptive immunity. The innate immunity provides early and non-specific response against microbes. The adaptive humoral and cellular immunity gives specificy for distinct molecules and has memory to enhance response to antigen and diversity to responde to large variety of antigen


Assuntos
Humanos , Linfócitos T/fisiologia , Sistema Imunitário/fisiologia , Fagocitose , Imunoglobulinas/ultraestrutura , Interleucinas , Via Clássica do Complemento , Células Matadoras Induzidas por Citocinas/fisiologia , Imunidade Adaptativa , Imunidade Humoral , Imunidade Inata , Anticorpos
13.
CES med ; 26(1): 85-98, ene.-jun. 2012. tab, graf
Artigo em Espanhol | LILACS | ID: lil-652809

RESUMO

Antecedentes: durante la ventilación mecánica las estructuras pulmonares están sometidasa fuerzas complejas e inusuales que son particularmente relevantes en la incitacióndel daño pulmonar. Las respuestas inflamatoria pulmonar y sistémica secundarias en el pacientede cirugía mayor y cardiovascular, es generada en gran parte por la sobredistención/compresión dela células alveolares y de los bronquiolos terminales, los flujos turbulentos de gases o fluidos al interiordel lumen bronquial, los fenómenos de isquemia/reperfusión pulmonar luego de la circulaciónextracorpórea y la consecuente activación del complemento, citoquinas y demás respuestas celularespro-inflamatorias.Métodos: se realizó una revisión de la literatura disponible en múltiples bases indexadas de literaturamédica (PubMed, ScieLO, Hinari y Cochrane) desde enero de 1990 hasta diciembre de2011, sobre estudios clínicos aleatorizados, estudios retrospectivos y guías de práctica clínica, queidentificaran las principales estrategias para ventilación mecánica protectora (VMP) en pacientes decirugía cardiovascular y cirugía mayor. Resultados y conclusiones: el modo óptimo de soporteventilatorio en cirugía cardiovascular y cirugíamayor continua siendo objeto de debate. La evidenciaexperimental y clínica sugiere que los bajos volúmenescorrientes, bajas presiones al final de la inspiración yla instauración de alta presión al final de la espiraciónpodrían reducir la injuria pulmonar asociada a la ventilaciónmecánica. Algunas recomendaciones actualescomo la utilización de volúmenes corrientes de 6 a 8 ml/kgdel peso ideal, han sido extractadas de grandes estudiosretrospectivos realizados en otro tipo de poblaciones.


Background: Lung structures are exposed tocomplex and unusual forces during mechanicalventilation. This phenomena is particularly relevantto induce lung damage due to overdistension,generation of turbulent flows of gases andfluids into the alveolar and peripheral bronchiallumen, induction of ischemia-reperfusion lesionand inmunological activation, which are greatlyresponsible of the secondary systematic inflammatoryresponse.Methods: A search of available medical literaturerelated to protective mechanical ventilation(PMV) in cardiovascular surgery and major surgerywas conducted using different medical databases(PubMed/MEDline, SciELO, Hinari andCochrane). RCTs, retrospective clinical studies,revision articles, case series, cases and controlsstudies, and clinical guides were reviewed.Results and conclusions: The optimal way forventilatory support in cardiovascular and majorsurgery is object to debate. Experimental evidencesuggests that ventilation with low tidalvolume, lowers pressure at the end of inspiration,and high pressure at the end of expiration,can reduce lung injury associated to ventilation.It was therefore recommended to use currentvolumes from 6 to 8 ml/Kg of the ideal weightand was defined by the Acute Respiratory DistressSyndrome Net as “protective pulmonaryventilation”. Based on studies carried out, thereis no convincing evidence that protective mechanicalventilation (Low VT with PEEP) lowersthe release of cytokines, transfusion needs, mechanicalventilation times, improve post-surgerypulmonary function or a decrease in mortality,intensive care or hospital stay compared to theconventional ventilation in cardiovascular ormajor surgery.


Assuntos
Humanos , Ponte Cardiopulmonar , Respiração Artificial , Cirurgia Torácica , Células Matadoras Induzidas por Citocinas
14.
CES odontol ; 25(1): 92-101, ene.-jun. 2012.
Artigo em Espanhol | LILACS | ID: lil-652822

RESUMO

En general, los factores genéticos influencian la respuesta inflamatoria e inmune, haciendo que losindividuos puedan responder de manera diferente a un mismo cambio en el ambiente. Así, el perfil genéticode cada individuo modula o influencia esa respuesta. La interleukina 1ß (IL-1 ß) es un potente activadorde la actividad osteoclástica y una variación genética de la proteína, conocida como polimorfismo, puedeaumentar su efecto, lo que afectaría negativamente el pronóstico en los tratamientos odontológicos. Elestudio de los polimorfismos genéticos de las interleuquinas se ha convertido en tema de gran interésy debate académico en diferentes ramas de la salud, debido a la importancia que parecen tener comomoduladores de los procesos de reabsorción ósea. Porque los polimorfismos genéticos pueden ayudar a explicar las diferentes respuestas al tratamiento endodóntico en diferentes pacientes. El propósito de estarevisión es actualizar la información previamente publicada relacionada con los polimorfismos genéticos.


Genetic factors influence inflammatory and immune responses in general, and individuals may responddifferently to common environmental challenges. Therefore the genetic profile for every individual moduleor influence that response. Interleukin 1ß (IL-1 ß) is a potent activator of osteoclastic activity and geneticvariation of the protein, known as polymorphism, may increase its effect, which would negatively affectthe prognosis of dental treatment. The study of genetic polymorphisms of interleukins has become atopic of great interest and academic debate in different areas of health, given the importance they seemto have as modulators of bone resorption processes. Because of the genetic polymorphisms might helpexplain the different responses to endodontic treatment in different patients, the purpose of this literaturereview is to update previously published information regarding genetic polymorphism.


Assuntos
Humanos , Células Matadoras Induzidas por Citocinas , Interleucina-1beta , Doenças Periodontais , Polimorfismo Genético
15.
Clin Transl Oncol ; 14(2): 102-8, 2012 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-22301398

RESUMO

China is the country where the most clinical trials on CIK cells have been performed. We aimed to provide definite evidence for using CIK cell treatment and extrapolate a common applicative standard for malignancies. We chose the VIP database of Chinese scientific and technological journals to search the literature. We entered the keywords "CIK" or "xi bao yin zi you dao de sha shang xi bao" (the equivalent Chinese phrase for CIK cells, by Chinese characters) and searched for in vivo human trials. In 24 collected trials, 936 patients were treated with CIK cells, 525 men and 246 women. The cultivation time of CIK cells ranged from 7 to 28 days. In five studies, CIK cells were co-cultured with dendritic cells. The total number of CIK cells used ranged from 6×10(6) to 1.5×10(10). The total number of DC-CIK cells used ranged from 1×10(9) to 1.3×10(10). In all studies, those immune parameters and tumour markers examined increased, but not all increased significantly. Of the reported 563 patients, 40 had a complete response, 126 had a partial response, 125 had a minimal response, 135 had stable disease and 58 had progressive disease. The remaining 76 patients did not reach an objective response. The total response rate was 51.7% (291/563). The toxicities were slight. CIK cell treatment is a promising and safe modality for treating malignancies. We proposed a standard for cultivating CIK cells.


Assuntos
Células Matadoras Induzidas por Citocinas/transplante , Neoplasias/terapia , China , Ensaios Clínicos como Assunto , Células Matadoras Induzidas por Citocinas/citologia , Feminino , Humanos , Masculino , Neoplasias/imunologia
16.
Colomb. med ; 37(2): 159-168, abr.-jun. 2006. ilus, tab
Artigo em Espanhol | LILACS | ID: lil-585812

RESUMO

Las células T asesinas naturales con receptor de células T invariante y restringidas por la molécula CD1d (iNKT) son un subgrupo de linfocitos con potente actividad inmunorreguladora; su respuesta casi inmediata y la capacidad de producir citoquinas tanto Th1 como Th2 son factores determinantes en el desarrollo de la respuesta inmune innata y adaptativa. El papel fisiológico de las células iNKT se ha documentado ampliamente en la respuesta anti-tumoral, el desarrollo de la tolerancia en los órganos inmunoprivilegiados y el control de las reacciones autoinmunes. A pesar de la demostrada potencia inmunomoduladora de las células iNKT, hasta el momento se conoce poco de su acción en la respuesta inmune anti-infecciosa, en particular en el ser humano y contra los virus patógenos. Este artículo sintetiza los resultados de una búsqueda en las principales bases de datos biomédicas (Pubmed, Medline y OVID), e incluye los estudios realizados para caracterizar estas células y evaluar su papel en la interacción del hospedero con los virus. Las células iNKT participan en la respuesta inmune antiviral, aunque de una manera diferente según el tipo de virus; incluso, podrían estar comprometidas en los daños mediados por mecanismos inmunes. En el ser humano, las células iNKT son aparentemente esenciales en la respuesta inmune contra el virus Varicela Zoster, mientras que todavía hay controversia sobre su función en el control de otros virus. Los modelos animales han aportado las primeras evidencias sobre el potencial de la manipulación terapéutica específica de este subgrupo de linfocitos.


Natural killer T cells with an invariant T-cell receptor and restricted by CD1d (iNKT) are a subgroup of lymphocytes with a very strong immunoregulatory potential; their quick response and their ability to produce Th1 and Th2 cytokines are determinant factors that influence the development of innate and adaptive immune responses. The physiological role of iNKT cells has been well documented in anti-tumor immune responses, the development of tolerance in immune-privileged organs and the control of autoimmune diseases. Despite the fact that the immunoregulatory potential of these cells has been well documented, less is known regarding their role in the immune response against infectious agents, in particular to human pathogenic viruses. This paper synthesizes the search in the most important biomedical data bases (Pubmed, Medline, OVID), including studies on the phenotypic characterization of these cells and functional studies that evaluated their role in the interaction between hosts and viruses. iNKT cells have a heterogeneous participation during the anti-viral immune responses, depending on the type of virus; indeed, in some instances the iNKT-cell responses can be involved in the tissue damage associated to the anti-viral responses. In humans, iNKT cells are apparently essential for an effective immune response against Varicella Zoster virus, while it is still controversial their role in the control of other viral infections. Studies in animal models have shown the first evidences on the therapeutic potential of this lymphocyte subpopulation.


Assuntos
Antígenos CD1d , Células Matadoras Induzidas por Citocinas , Galactosilceramidas , HIV , Linfócitos T , Viroses
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA